- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg
- Drug
- Lead sponsor
- Leonard Feiner, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Teaneck, New Jersey • Vauxhall, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Aflibercept, Triamcinolone Acetonide, Verteporfin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Macular Degeneration, Maculopathy, Age-Related
- Interventions
- anecortave acetate
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Retinal Disease, Macular Disease
- Interventions
- Interferon gamma-1b
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
- Interventions
- Advanced multi-component meditation practice
- Behavioral
- Lead sponsor
- Tobias Moeller-Bertram
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Palm Desert, California
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- AGN208397 intravitreal injection, dexamethasone intravitreal implant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Retinal Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Geographic Atrophy
- Interventions
- Tinlarebant, Placebo
- Drug
- Lead sponsor
- Belite Bio, Inc
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 19 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Squalamine lactate, Vehicle control
- Drug
- Lead sponsor
- Ohr Pharmaceutical Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Bakersfield, California • Beverly Hilss, California + 17 more
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy
- Interventions
- Not listed
- Lead sponsor
- Carl Zeiss Meditec, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Oakland, California • Jackson, Michigan
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- EYC-0305
- Biological
- Lead sponsor
- Eyconis INC.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Modesto, California • Wake Forest, North Carolina + 4 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- RetnaGene AMD LDT
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Uveitis, Macular Edema
- Interventions
- Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
- Drug
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
- Conditions
- Geographic Atrophy
- Interventions
- Sirolimus, Lidocaine
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 13
- States / cities
- Loma Linda, California • Sacramento, California • Jacksonville, Florida + 10 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more
- Conditions
- Macular Degeneration
- Interventions
- abicipar pegol, ranibizumab, sham procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Hypotony Ocular, Cornea Folds and Rupture of Bowman's Membrane Both Eyes, Maculopathy
- Interventions
- Ophthalmic imaging
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 77
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more
- Conditions
- Macular Degeneration
- Interventions
- AdGVPEDF.11D
- Drug
- Lead sponsor
- GenVec
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Los Angeles, California • Boynton Beach, Florida + 5 more
- Conditions
- Macular Degeneration
- Interventions
- Lucentis, Ranibizumab, Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- The National Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Chevy Chase, Maryland • Towson, Maryland
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- AL-78898A, Ranibizumab
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Aliskiren, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more